Agent possessing general strengthening and antioxidant action

FIELD: pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an agent possessing general tonic, antioxidant action. Agent contains apple pectin, source of biologically active substances (BAS), glutathione, amino acids, potassium sorbate, water with negative oxidation-reduction potential from -200 to -240 mV, taken in a certain amount. BAS source is selected from: extract of red wine, and/or extract of hawthorn fruits, and/or cranberry fruit extract, and/or rosehips extract with vitamin C, and/or extract of spinach, and/or extract of stems and pineapple fruits, and/or celery extract, and/or red bilberry extract, and/or extract of juniper, and/or melon extract, and/or orange extract, and/or oat extract, and/or extract of black currants, and/or sprouts extract broccoli, and/or ginger root extract, and/or mango extract, and/or walnut extract, and/or extract of berries, and/or extract of green tea, and/or Bilberry fruit extract, and/or raspberry extract and/or quercetin, and/or soya isoflavones. Amino acid selected from: alanine, and/or aspartic acid, and/or glutamine, and/or glutamic acid, and/or arginine, and/or leucine, and/or lysine, and/or proline.

EFFECT: agent described above possesses the pronounced general tonic, antioxidant action, increased storage life.

4 cl, 9 ex



Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to selenium nanocomposites of natural hepatotrophic galactose-containing polysaccharide matrixes, representing water-soluble orange-red powders containing zerovalent selenium (Se0) nanoparticles sized 1-100 nm in the quantitative content of 0.5 - 60 wt %, possessing antioxidant activity for treating and preventing redox-related pathologies, particularly for treating toxic liver damage, to a method for producing and to an antioxidant agent containing the above nanocomposites.

EFFECT: invention provides the targeted agent delivery to liver cells, as well as higher agent accessibility and lower toxic action of selenium.

7 cl, 11 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: method involves chelation of ferric (III) ions both in vivo, and in vitro with using 2-ethyl-6-methyl-3-hydroxypyridine succinate (Mexidol) to produce a stable stained complex having a high molecular weight and a complex (organic-inorganic) composition not identified among the known compounds.

EFFECT: high effectiveness of the chelation process and low toxicity of Mexidol that makes it promising for biomedical application.

4 dwg, 3 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to field of organic chemistry, namely to novel compound - 5(6)-nitro-1-(thietanyl-3)-2-ethoxybenzimidazole, inhibiting peroxidation of lipids.

EFFECT: novel compound, possessing useful biological properties, has been obtained.

2 cl, 1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention represents a mixture of two structural isomers: 2,6-di(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-4-methylphenol and its diastereomers, and 2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-6-(2,2,1-trimethylbicyclo[2.2.1]hept-5-yl)-4-methylphenol, and their diastereomers with the ratio of the first and second structural isomer isomers from 60:40 wt % to 95:5 wt %.

EFFECT: extension of the arsenal of means, possessing simultaneously haemorheological, anti-aggregate, anti-thrombogenic, retinoprotecting, endothelium-protecting, neuroprotecting, anti-arrhythmia and anti-ischemic activity, enhancing the cerebral blood flow.

4 dwg, 20 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: what is presented is using Histochrom (same as echinochrome A or pentahydroxyethyl naphthoquinone) as an agent able to prevent pulmonary fibrosis developed under cytostatic agents. The invention can be used for the pharmacological prevention and correction of the pulmonary tissue disorders caused by administering the cytostatic agents.

EFFECT: preventing hypertrophy of interalveolar connective tissue in the lungs associated with administering bleomycin.

4 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.

EFFECT: drops possess pronounced antiviral and immunomodulatory effects.

15 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: melanin having water-solubility of at least 80% and an paramagnetic centre concentration of at least 8·1017 spin/g is administered orally into the animals having been exposed to the radiation in a dose high enough to cause a spinal radiation injury; melanin is administered after dissolved in distilled water in the effective concentration. Melanin water is used as drinking water for the mice having been exposed to single and fractionated acute radiation, which is able to cause acute radiation disease. Melanin water is taken from the 1st to 30th day following the single radiation, or from the 1st day of the fractionated radiation to the 30th day on completion of the radiation.

EFFECT: higher survival rate, faster recovered haemopoiesis, body weight and orientation and motion activity.

7 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention provides a composition having antioxidant properties in the form of a tablet, comprising an active agent based on nicotinamide adenine dinucleotide in reduced form (NADH) and inert filling agents, characterised by that the active ingredient is a complex which is a mixture of 10 wt % NADH with 63 wt % vegetable fats, 17 wt % beeswax and 10 wt % chlorophyll, and the inert filling agents are in the form of microcrystalline cellulose, Macrogol 6000, intense sweetener and a food flavourant.

EFFECT: invention provides a new tablet form of NADH.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to a pharmaceutical composition with anti-ischemic and antioxidant activity in the form of tablets or capsules, and a method for preparing it. The composition contains 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid in an amount of 40 to 80 wt %, an amino-containing compound and pharmaceutically acceptable excipients. The amino-containing compound is specified in a group of trometamol, methyl glucamine and L-lysine; 1 mole of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid is accounted for 0.05 to 0.25 mole of the above amino-containing compound. The composition also contains lactose, microcrystalline cellulose, calcium stearate and other pharmaceutically acceptable excipients. According to the method for preparing the composition, taking 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid and amino-containing compound in molar ratio 1:0.05 to 1:0.25, pre-mixing, moisturising with a aqueous or alcohol solution of a binding agent, adding pharmaceutically acceptable excipients in such an amount to provide the content of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid from 40 to 80 wt %, granulating the mixture, drying and producing tablets or capsules according to the known technique.

EFFECT: implementing the above application.

6 cl, 7 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: claimed is the application of 5(6)-nitro-1-(1,1-dioxothietanyl-3)-2-chlorobenzimidazole of formula (I) , earlier known as the means with broncholytic and spasmolytic activity, as the means, inhibiting peroxide oxidation of lipids.

EFFECT: realisation of the claimed purpose.

1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely represents composition, which contains mixture of particles of hydrophobic silicon dioxide aerogel, which have specific area of surface per weight unit (Sw) in range from 500 to 1500 m2/g and size, expressed in form of volume mean diameter (D[0.5]), in range from 1 to 1500 mcm, and at least one first linear silicone oil, which has viscosity higher than 50 mm2/s, and at least second and third linear silicone oils, and each of them has viscosity lower than or equal 50 mm2/s.

EFFECT: mixture of particles of silicon dioxide aerogel and linear oils provides possibility of obtaining compositions, which provide comfort and smoothness of skin after application and have dullness and "soft focus"-adding properties.

23 cl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to an antiseptic pharmaceutical composition applicable for oral hygiene and treatment of microbial oral diseases, to a method for producing and using it. The composition contains from 0.05 to 0.3 wt % of hydrogen peroxide or its equivalent amount in the form of carbamide peroxide, from 0.001 to 0.03 wt % of eugenol, from 0.001 to 0.01 wt % of camphor, from 0.001 to 0.5 wt % of a salt of zinc or other heavy metals, such as silver, mercury, copper or a mixture thereof; from 1 to 1.2 wt % of sodium fluoride; from 2% to 7 wt % of xylitol, from 0.002 to 0.05 wt % of cetylpyridinium chloride and excipients in an amount sufficient to reduce the composition to 100%. The composition possesses a wide spectrum of action. What is also presented is a method for producing the composition and using it for producing a therapeutic agent effective for odour elimination, suppression and relief of an oral inflammation, dental tartar inhibition; for treating oral diseases; for rinsing and treating orthodontic damages; for preventing oral diseases during orthodontic treatment after oral operations and in the patients using fixed and temporary dentures; for relieving, treating or preventing oral diseases in different categories of patients, such as the patients receiving radiation therapy or chemotherapy, hospital patients and terminally ill patients, patients suffering from eating disorders, endocrine, haematological, cardiovascular and psychosomatic disorders, and besides physically or mentally deprived patients, patients with genetic or inherited changes.

EFFECT: preparing the antiseptic pharmaceutical composition.

22 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for preparing a medicinal product possessing choleretic activity. The medicinal product possessing choleretic activity and prepared by extracting an elevated part of Lomatogonium carinthiacum in 96% ethanol twice at room temperature, them in 40% ethanol with an extractant added in an amount equal to a discharged one, twice; the filtered aqueous-alcoholic extracts are combined; the extraction cake is extracted in purified water; the aqueous extract is filtered; the aqueous residues of the aqueous-alcoholic extracts are combined with the aqueous extract, concentrated, dried in a vacuum drying cabinet to produce the dry extract in the certain environment.

EFFECT: medicinal product prepared as described above possesses the evident choleretic activity.

11 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and is intended for oral cavity care. Compositions contain non-dialysable material of cranberry extract, in which non-dialysable material of cranberry extract is present in quantity, effective for inhibiting co-aggregation of oral cavity bacteria and/or inhibiting bacterial growth.

EFFECT: group of inventions makes it possible to increase efficiency of oral cavity care due to inhibition of bacterial growth and co-aggregation of bacteria.

15 cl, 5 tbl, 4 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises subcutaneous administration of antibiotic preparation enroxyl 5% at a dose of 0.1 ml/kg daily one time a day for 7 days and intramuscular administration of homeopathic preparation ovarinin at a dose of 1 ml/kg one time for 4 days, 4-fold.

EFFECT: use of the invention enables to increase the efficiency of treatment, to reduce treatment time and to restore reproductive function of dogs.

2 tbl, 1 ex

Black adler syrup // 2557929

FIELD: medicine.

SUBSTANCE: black adler syrup having laxative action, characterised by the fact that it is produced by preparing black adler tea by boiling the raw material with purified water; the tea is further mixed with refined sugar; the mixture is heated until the sugar is dissolved completely and brought to boil twice with skimming as often as it may be required; the prepared syrup is filtered through gauze in the certain environment.

EFFECT: syrup is high in anthracene derivatives and possesses the pronounced laxative action.

2 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and cosmetology, namely to deep cosmetic products, and can be used for normalising physiological functions of skin and eliminating endogenous or exogenous defects. The invention represents a cosmetic product for fast skin repair containing superoxide dismutase, dexpanthenol, succinic acid, trolox and L-arginine. The product is applied on the skin for 20 minutes with using a material holding the agent and feeding it to the skin over the period of exposure.

EFFECT: cosmetic product enables extending the range of products for improving the skin state, reducing the risk of lower controllability of the effect, and a probability of allergic and inflammatory reactions.

3 cl, 10 ex

FIELD: medicine.

SUBSTANCE: using a polyphenolic complex produced by extracting milled ash berry in 40% ethanol, condensing the alcohol-water extract, adding 95% ethanol, centrifuging the residue, filtering and condensing the supernatant in the certain environment, as an agent possessing anti-inflammatory action.

EFFECT: polyphenolic complex possesses pronounced anti-inflammatory action.

1 dwg, 9 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to veterinary science and is applicable for treating bovine mastitis. What is declared is a nosode for producing a preparation for treating bovine mastitis. That involves taking mastitis milk 1 ml with clinical signs of purulent-catarrhal mastitis, filling it 70° alcohol 9 ml to produce a homogenous solution; the produced solution is diluted to "Д6" with 70° alcohol. What is also declared is a preparation for treating bovine mastitis containing an aqueous-alcoholic solution of components. The components are Belladonna, Sulphur, Apis mellifica, Conium, Phytolacca, Silicea and above nosode in the following proportions, wt %: Belladonna - 5, Sulphur - 20, Apis mellifica - 20, Conium - 10, Phytolacca - 10, Silicea - 5, nosode - 15, aqueous-alcoholic solution up to 100%. What is also declared is a method of treating bovine mastitis involving the intracisternal administration of the preparation. The preparation is administered in a dose of 5-10 ml per 1 animal once a day.

EFFECT: declared group of inventions is highly effective in treating bovine mastitis.

3 cl, 5 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical composition, containing compound of formula or for prevention or treatment of diseases, associated with oxidative stress, selected from group, consisting of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke episodes), MERRF syndrome (myoclonic epilepsy with ragged red fibres) or Kearns-Sayre syndrome, arrhythmia, cardioplegia or myocardium infarction. in formula (1) na stands for 1 or 2, Aa represents 5-membered heteroaryl or heterocycle, each of which has 2 heteroatoms, selected from N, O and S, Rla represents R5a-Xa-Ba-X′a-, Ba represents direct bond, Xa and X′a independently on each other represent direct bond or -OC(O)-, R5a represents hydrogen or 6-9-membered monocyclic or condensed cyclic heterocycle or heteroaryl, each of which has from 1 to 3 heteroatoms, selected from N, O and S, and is optionally substituted with oxo or C1-C6-alkyl, R2a represents -(CR8aR9a)pa-Ya-R7a, pa stands for number from 0 or 1, Ya represents direct bond or -O-, R7a represents hydrogen or phenyl, R3a, R8a, R9a, R10a represent hydrogen, R4a represents -(CH2)pa-Da-R10a-, Da represents C5-cycloalkyl or 6-membered heterocycle, which has 1 heteroatom, selected from N, S and O. Radical values for formula (2) are give in invention formula.

EFFECT: obtaining compositions for prevention or treatment of diseases, associated with oxidative stress.

19 dwg, 5 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry, namely to a method of obtaining pectins from a biomass of cultured tissues of plants Silene vulgaris (M.) G. The method of obtaining pectins with an increased content of galactose residues in side carbon chains from Calusa cultures includes raw material destruction, extraction with water, processing of the biomass with hydrochloric acid, water washing, extraction with ammonium oxalate solution, sedimentation of polysaccharide with ethanol, dialysis and lyophilising, with Caluse cultures being preliminarily grown for 21 hours on an agarised nutrient medium, which contains the ferment 1,4-β-D-galactozyltranspherase in a specified concentration, and as the raw material the biomass of cultured tissues of plants Silene vulgaris is applied.

EFFECT: method makes it possible to obtain physiologically active pectins, which have a specified structure and stable chemical composition.

1 tbl, 4 ex